The Cockcroft-Gault equation estimates creatinine clearance (CrCl) from age, serum creatinine, a selected body weight and the equation's sex factor. This Guide explains how the equation works, why the weight choice changes the result, and why current medicine sources do not all use the same renal estimate.
What Cockcroft-Gault calculates
Cockcroft-Gault produces an estimated creatinine clearance in mL/min. It is not a directly measured GFR, a CKD stage or a medicine dose. The equation remains relevant because some medicine labels, dosing references and protocols still specify Cockcroft-Gault CrCl.
If you only need the arithmetic, use the Creatinine Clearance Calculator. Continue here for the equation background, weight-selection considerations and interpretation context.
The Cockcroft-Gault equations
For serum creatinine in µmol/L:
CrCl (mL/min) = [(140 − age) × weight × sex factor] ÷ (0.814 × serum creatinine)
For serum creatinine in mg/dL:
CrCl (mL/min) = [(140 − age) × weight × sex factor] ÷ (72 × serum creatinine)
The conventional historical equation factor is 1.0 for male and 0.85 for female. The calculator requires the factor to be selected explicitly rather than silently defaulting to one value.
Where the equation came from
Donald W. Cockcroft and M. Henry Gault published the equation in Nephron in 1976. The derivation used 249 adult male patients, and the 15% lower female estimate was an adjustment rather than a separately derived female model. That historical design is one reason Cockcroft-Gault should be treated as an estimating equation rather than a direct measurement of filtration.
Which weight should you use?
There is no universal MedMaths rule that chooses actual body weight, ideal body weight (IBW) or adjusted body weight (AdjBW) for every medicine and every patient. Weight choice can materially change the CrCl result, especially at body-size extremes.
- Actual body weight: the patient's current measured weight.
- Ideal body weight: a height-based estimate such as Devine IBW.
- Adjusted body weight: a derived value that may be specified by some sources. In the MedMaths helper, the 0.4 adjusted-weight value is calculated only when actual weight is above Devine IBW; it is not manufactured when actual weight is at or below IBW.
Use the weight method stated by the medicine information, dosing reference or local protocol you are following. Winter and colleagues found that different weight descriptors performed differently across body-size groups, including better performance of actual weight in their underweight group and adjusted weight with a 0.4 factor in overweight/obese groups. That study does not create a universal dosing-weight rule. If the source is unclear and the choice could change a dosing band, confirm the method rather than allowing a calculator to choose automatically.
MedMaths provides separate IBW and AdjBW calculators to make the arithmetic transparent when those values are explicitly required.
Cockcroft-Gault and eGFR are not interchangeable names
CKD-EPI eGFR and Cockcroft-Gault CrCl use different equations and can produce different numerical estimates. Current guidance is more nuanced than the old shorthand “eGFR for CKD, CrCl for drugs”: contemporary eGFR is used for many dosing decisions, while particular medicines and circumstances may still specify Cockcroft-Gault CrCl.
The practical rule is to use the renal estimate and units required by the current source. If the source names CKD-EPI 2021 eGFR, use the eGFR Calculator rather than forcing the decision through Cockcroft-Gault. For the detailed comparison, read eGFR vs CrCl.
Important limitations
- Changing serum creatinine: the equation assumes a relatively steady creatinine concentration and can lag during acute kidney injury or other rapid change.
- Creatinine generation: frailty, very low or high muscle mass, amputation and other body-composition differences can reduce accuracy.
- Weight choice: different weight conventions produce different CrCl estimates, and evidence does not support one weight descriptor across every body size, medicine and protocol.
- Historical binary coefficient: the original study did not establish a universally validated factor-selection rule for transgender, nonbinary or intersex people. Published transgender data show that the choice of binary equation term can materially change creatinine-based estimates.
- Creatinine assay era: Cockcroft-Gault predates modern IDMS-traceable creatinine standardisation. NKF notes that standardized creatinine values can make current eCrCl estimates higher than values obtained in older pharmacokinetic studies used for some legacy dosing recommendations.
- Estimate, not measurement: CrCl estimated by Cockcroft-Gault is not identical to measured GFR or measured creatinine clearance.
- Medicine-specific thresholds: the equation does not decide a dose, interval, contraindication or dialysis adjustment.
Current guidance in plain English
The National Kidney Foundation now advocates transitioning adult medication-related decisions away from Cockcroft-Gault eCrCl toward race-free eGFR, with individual BSA adjustment when appropriate. FDA's 2024 renal-impairment guidance specifically recommends eGFR over eCrCl for pharmacokinetic studies. At the same time, NIDDK, UK MHRA and NHS Specialist Pharmacy Service material makes clear that existing medicine labels and clinical situations may still name a particular renal estimate. The practical MedMaths rule is therefore: follow the estimate and units required by the current governing source rather than automatically substituting one method for another.
Sources
- Cockcroft & Gault 1976 original publication (PubMed)
- National Kidney Foundation: Cockcroft-Gault limitations and transition guidance
- NKF Workgroup consensus: transition from Cockcroft-Gault to race-free eGFR for medication-related decisions
- Winter et al. 2012: body-weight and serum-creatinine effects on Cockcroft-Gault accuracy
- Fadich et al. 2022: creatinine-based kidney estimates in transgender adults
- 2026 pharmacist study: binary sex variables in transgender clinical calculations
- NIDDK: Determining Drug Dosing in Adults with CKD
- FDA 2024 renal-impairment pharmacokinetics guidance
- UK MHRA: choosing the appropriate renal-function estimate
- NHS SPS: Calculating kidney function